SEC Form 4 · accession 0001209191-17-005990
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew J D'Onofrio
Officer — Exec VP, Chief Bus. Officer
Period of report
Jan 25, 2017
Accepted (ET)
Jan 27, 2017 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.36 | Jan 25, 2017 | A | 150,000 | A | — | Jan 24, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2017, subject to the reporting person's continued service to the Issuer through each such vesting date.